Vertex To Release Q3 2012 Hep C Revenue Data Monday

FINAL UPDATE | 11.01.12:Vertex reports that (as I predicted) 75 percent of all new Hep C current-gen patients — some $254 million worth in Q3 2012, alone — are receiveing Incivek, over Victrelis (New Merck/legacy Schering-Plough). However, it seems many of the less severely afflicted Hep C positive patients are waiting — deferring any treatment — for the arrival of the all-oral next-gen Hep C “cures” now in Phase II/III clinical trials.

On Thursday Next up, on Monday evening, Vertex Pharmaceuticals reports its third quarter revenue from telaprevir, branded as Incivek. I expect at least a 75-25 advantage in market share, for Vertex, over the rival Merck (actually, legacy Schering-Plough) drug, boceprevir.

But we shall see. You may tune in here:

. . . .As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29. Vertex will now announce its third quarter 2012 financial results on Thursday, November 1, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT on Thursday. . . .
. . . .Oct 29, 2012 | 5:00 PM ET

Vertex Pharmaceuticals Incorporated Third Quarter 2012 Financial Results Conference Call.  . . .

We will report on it, then. As ever, be careful out there.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s